«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 08

Page:

1549-1553

Research Field:

Publishing date:

Info

Title:

Research status of biomarkers in expressed prostatic secretion-urine for prostate cancer

Author(s):

DONG Qifei¹; WANG Changming²; TAO Tao²; XIAO Jun¹; 2

1.Affiliated Anhui Provincial Hospital of Anhui Medical University,Anhui Hefei 230001,China;2.Department of Urology,the First Affiliated Hospital of University of Science and Technology of China£¨Anhui Provincial Hospital£©,Anhui Hefei 230001,China.

Keywords:

prostate cancer; biomarkers; expressed prostatic secretion; EPS-urine

PACS:

R737.25

DOI:

10.3969/j.issn.1672-4992.2024.08.032

Abstract:

As our country has gradually entered the aging society,prostate cancer has become the most common tumor of the reproductive system in the elderly male population.Prostate biopsy is currently the gold standard for the diagnosis of prostate cancer,but patients often choose to refuse at presentation because of its low positive rate and more postoperative complications.At the same time,prostate cancer is also highly heterogeneous,and the prognostic risk grouping of patients is still a major challenge.Therefore,it is of great clinical significance to explore biomarkers for diagnosis and prognosis.After intensive study of expressed prostatic secretion(EPS)-urine,more and more kinds of protein species and metabolites have been discovered,and predictive models built as biomarkers have been proposed.This article reviews the research status of biomarkers in EPS-urine for prostate cancer.

References:

£Û1£Ý SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023£ÛJ£Ý.CA Cancer J Clin,2023,73(1):17-48.
£Û2£Ý XIA CF,DONG XS,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants£ÛJ£Ý.Chin Med J (Engl),2022,135(5):584-590.
£Û3£Ý MOTTET N,VAN DEN BERGH RCN,BRIERS E,et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update.Part 1:Screening,diagnosis,and local treatment with curative intent£ÛJ£Ý.Eur Urol,2021,79(2):243-262.
£Û4£Ý MOSES KA,SPRENKLE PC,BAHLER C,et al.NCCN guidelines¡k insights:prostate cancer early detection,version 1.2023£ÛJ£Ý.J Natl Compr Canc Netw,2023,21(3):236-246.
£Û5£Ý FILSON CP,NATARAJAN S,MARGOLIS DJ,et al.Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy:The role of systematic and targeted biopsies£ÛJ£Ý.Cancer,2016,122(6):884-892.
£Û6£Ý KASIVISVANATHAN V,RANNIKKO AS,BORGHI M,et al.MRI-targeted or standard biopsy for prostate-cancer diagnosis£ÛJ£Ý.N Engl J Med,2018,378(19):1767-1777.
£Û7£Ý ³ÂÈñ,лÁ¢Æ½,ÖÜÀûȺ,µÈ.ÖйúÇ°ÁÐÏÙ°©ÁªÃ˳ÉԱҽԺǰÁÐÏÙ´©´Ì»î¼ìÏÖ×´µÄµ÷²é±¨¸æ£ÛJ£Ý.ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾,2015,36(5):342-345. CHEN Rui,XIE Liping,ZHOU Liqun,et al.Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals£ÛJ£Ý.Chinese Journal of Urology,2015,36(5):342-345.
£Û8£Ý ZHANG EC,SHIORI F,MU OY,et al.Establishment of novel DNA methylation-based prostate cancer subtypes and a risk-predicting eight-gene signature£ÛJ£Ý.Front Cell Dev Biol,2021,9:639615.
£Û9£Ý NIKANJAM M,KATO S,KURZROCK R.Liquid biopsy:current technology and clinical applications£ÛJ£Ý.J Hematol Oncol,2022,15(1):131.
£Û10£Ý ALAHDAL M,PERERA RA,MOSCHOVAS MC,et al.Current advances of liquid biopsies in prostate cancer:Molecular biomarkers£ÛJ£Ý.Mol Ther Oncolytics,2023,30:27-38.
£Û11£Ý LONE SN,NISAR S,MASOODI T,et al.Liquid biopsy:a step closer to transform diagnosis,prognosis and future of cancer treatments£ÛJ£Ý.Mol Cancer,2022,21(1):79.
£Û12£Ý DRAKE RR,WHITE KY,FULLER TW,et al.Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease£ÛJ£Ý.J Proteomics,2009,72(6):907-917.
£Û13£Ý PRESTAGIACOMO LE,TRADIGO G,ARACRI F,et al.Data-independent acquisition mass spectrometry of EPS-urine coupled to machine learning:A predictive model for prostate cancer£ÛJ£Ý.ACS Omega,2023,8(7):6244-6252.
£Û14£Ý PRINCIPE S,KIM Y,FONTANA S,et al.Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine£ÛJ£Ý.J Proteome Res,2012,11(4):2386-2396.
£Û15£Ý KIM Y,IGNATCHENKO V,YAO CQ,et al.Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer£ÛJ£Ý.Mol Cell Proteomics,2012,11(12):1870-1884.
£Û16£Ý LIU QP,WANG GY,LI QQ,et al.Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer£ÛJ£Ý.Int J Cancer,2019,145(2):415-426.
£Û17£Ý ÍõÕé·«,Ðì³½,³Â½¨´º,µÈ.Ç°ÁÐÏÙÒºÖÐEZH2±í´ï¶ÔÇ°ÁÐÏÙ°©ÁÙ´²Õï¶Ï¼ÛÖµµÄÑо¿£ÛJ£Ý.ʵÓÃÖ×ÁöÔÓÖ¾,2022,37(03):248-252. WANG Zhenfan,XU Chen,CHEN Jianchun,et al.Value of EZH2 expression in expressed prostatic secretion in diagnosis of prostate cancer£ÛJ£Ý.Journal of Practical Oncology,2022,37(03):248-252.
£Û18£Ý GULATI R.Reducing prostate cancer overdiagnosis£ÛJ£Ý.N Engl J Med,2022,387(23):2187-2188.
£Û19£Ý WOLF AM,WENDER RC,ETZIONI RB,et al.American Cancer Society guideline for the early detection of prostate cancer:update 2010£ÛJ£Ý.CA Cancer J Clin,2010,60(2):70-98.
£Û20£Ý DRAGO D,ANDOLFO A,MOSCA E,et al.A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer£ÛJ£Ý.Cancer Biol Med,2021,18(2):604-615.
£Û21£Ý ZHANG M,CHEN LZ,YUAN ZW,et al.Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers£ÛJ£Ý.Discov Med,2016,22(122):281-295.
£Û22£Ý SHAO XG,PAN JH,WANG YQ,et al.Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer,a preliminary study£ÛJ£Ý.Nanomedicine,2017,13(3):1051-1059.
£Û23£Ý CHEN LZ,ZHANG EC,GUAN J,et al.A combined CRISP3 and SPINK1 prognostic grade in EPS-urine and establishment of models to predict prognosis of patients with prostate cancer£ÛJ£Ý.Front Med (Lausanne),2022,9:832415.
£Û24£Ý SHAO HL,IM H,CASTRO CM,et al.New technologies for analysis of extracellular vesicles£ÛJ£Ý.Chem Rev,2018,118(4):1917-1950.
£Û25£Ý CHEUNG AH,CHOW C,TO KF.Latest development of liquid biopsy£ÛJ£Ý.J Thorac Dis,2018,10(Suppl 14):S1645-S1651.
£Û26£Ý DUIJVESZ D,LUIDER T,BANGMA CH,et al.Exosomes as biomarker treasure chests for prostate cancer£ÛJ£Ý.Eur Urol,2011,59(5):823-831.
£Û27£Ý SALCICCIA S,FRISENDA M,BEVILACQUA G,et al.Exosome analysis in prostate cancer:How they can improve biomarkers' performance£ÛJ£Ý.Curr Issues Mol Biol,2023,45(7):6085-6096.
£Û28£Ý CORRELL VL,OTTO JJ,RISI CM,et al.Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in-depth proteomic analysis£ÛJ£Ý.J Extracell Vesicles,2022,11(2):e12184.
£Û29£Ý PRINCIPE S,JONES EE,KIM Y,et al.In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine£ÛJ£Ý.Proteomics,2013,13(10-11):1667-1671.
£Û30£Ý ZAICHICK V£¬ZAICHICK S.Relations of the Al,B,Ba,Br,Ca,Cl,Cu,Fe,K,Li,Mg,Mn,Na,P,S,Si,Sr,and Zn mass fractions to morphometric parameters in pediatric and nonhyperplastic young adult prostate glands£ÛJ£Ý.Biometals,2014,27(2):333-348.
£Û31£Ý MEDAROVA Z,GHOSH SK,VANGEL M,et al.Risk stratification of prostate cancer patients based on EPS-urine zinc content£ÛJ£Ý.Am J Cancer Res,2014,4(4):385-393.
£Û32£Ý GONG YM,LIN ZD,GAN X,et al.Diagnostic potential of trace metals concentration in expressed prostatic secretion and serum of patients with category IV prostatitis£ÛJ£Ý.J Trace Elem Med Biol,2021,68:126819.

Memo

Memo:

National Natural Science Foundation of China(No.82072807£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨±àºÅ£º82072807£©£»°²»ÕÊ¡×ÔÈ»¿Æѧ»ù½ð£¨±àºÅ£º2108085MH293£©

Common functions

Last Update: 1900-01-01